Initial

Blackrock Silver Enters into Option Agreement with Tearlach Resources to Develop the Tonopah North Lithium Project

Retrieved on: 
Tuesday, January 10, 2023

Information concerning the discovery of lithium during the Company's first exploration drill program on the Tonopah North Project was announced in the Company's news release dated October 25, 2022.

Key Points: 
  • Information concerning the discovery of lithium during the Company's first exploration drill program on the Tonopah North Project was announced in the Company's news release dated October 25, 2022.
  • The exploration and development rights conferred to Tearlach under the Option Agreement in respect of the Tonopah North Project are exclusive to lithium minerals in the Optioned Zone.
  • Subject to the terms of the Option Agreement, Blackrock retains and reserves the rights to explore for, develop and mine all minerals (including gold and silver) other than lithium on the entire Tonopah North Project, including the Optioned Zone.
  • Upon Tearlach completing the Initial Earn-In and exercising the First Option, Tearlach and Blackrock Gold shall enter into a definitive mining joint venture agreement (the "Joint Venture Agreement") in respect of the management and ownership of the Optioned Zone of the Tonopah North Project (the "Joint Venture").

Tearlach Enters Into a Joint Venture Agreement With Blackrock Silver to Develop the Tonopah North Lithium Project, Nevada

Retrieved on: 
Tuesday, January 10, 2023

Morgan Lekstrom, CEO of Tearlach, commented, “This is a significant growth step for Tearlach in becoming a leading multijurisdictional lithium company and for Blackrock Silver diversifying their already world-class silver project.

Key Points: 
  • Morgan Lekstrom, CEO of Tearlach, commented, “This is a significant growth step for Tearlach in becoming a leading multijurisdictional lithium company and for Blackrock Silver diversifying their already world-class silver project.
  • Upon Tearlach completing the Initial Earn-In and exercising the First Option, Tearlach and Blackrock Gold shall enter into a definitive mining joint venture agreement (the “Joint Venture Agreement”) in respect of the management and ownership of the Optioned Zone of the Tonopah North Project (the “Joint Venture”).
  • The parties to the Joint Venture shall contribute to future Expenditures in accordance with their respective participating interests as prescribed in the Joint Venture Agreement.
  • Subject to the terms of the Joint Venture Agreement, Tearlach shall be the initial manager of the Joint Venture and shall have control of the activities and operations of the Joint Venture.

G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib

Retrieved on: 
Monday, January 9, 2023

RESEARCH TRIANGLE PARK, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the 2023 data readouts that are expected to drive its near-term and long-term indications and potential future treatment paradigms for some of the most aggressive and refractory cancers, including metastatic colorectal (mCRC), bladder or urothelial cancer (mUC), and triple negative breast cancer (TNBC).

Key Points: 
  • “But the high toxicity of these cytotoxic agents poses a risk of serious adverse events that can compromise patient well-being and patient outcomes.
  • Depending on the tumor type and the chemotherapy backbone, this mechanistic profile can drive patient benefits of myeloprotection and/or anti-tumor efficacy.
  • Initial results provided in January 2023 indicate that the confirmed objective response rate as of the cutoff date was comparable between arms.
  • G1 expects to release initial PFS data from PRESERVE 1 on the combination of trilaciclib administered prior to FOLFOXIRI and bevacizumab in 4Q23.

Sail Into Web3 With the Crypto Ark: Bybit Looks Ahead in Year End Keynote Address

Retrieved on: 
Sunday, January 22, 2023

Sail Into Web3 With the Crypto Ark: Bybit Looks Ahead in Year End Keynote Address

Key Points: 
  • Sail Into Web3 With the Crypto Ark: Bybit Looks Ahead in Year End Keynote Address
    Sail Into Web3 With the Crypto Ark: Bybit Looks Ahead in Year End Keynote Address
    Dubai, United Arab Emirates | January 05, 2023 08:45 AM Eastern Standard Time
    Ben Zhou, co-founder and CEO of Bybit, the third most visited cryptocurrency exchange in the world, shared Bybit's journey in becoming a Crypto Ark and a gateway to empower users to level up to Web3 in a candid exchange at a virtual event last week.
  • In a rollercoaster year that saw many peees succumb to market adversity, Bybit delivered its “Best 10”:
    Brand 3.0 for Web 3.0.
  • Over half a million new users started their crypto journey on Bybit with the exchange’s zero fees campaign in 2022.
  • He said the idea behind Bybit's Web3 push was to enable users to explore more with fewer clicks, starting with the Bybit Web3 Wallet.

XOMA Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Saturday, January 7, 2023

The First Hughes Inducement Award will vest in a series of four equal installments on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023.

Key Points: 
  • The First Hughes Inducement Award will vest in a series of four equal installments on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023.
  • The Second Hughes Inducement Award will vest in a series of 36 successive equal monthly installments measured from January 1, 2023.
  • The Inducement Awards are subject to the terms and conditions of the Company's Amended and Restated 2010 Long Term Incentive and Stock Award Plan but were granted outside the plan as an inducement material to each of Mr. Hughes and Mr. Sitko entering into employment with XOMA in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Inducement Awards also have a ten-year term and are each subject to the terms and conditions of the stock option agreement pursuant to which each such Inducement Award was granted.

Worldwide Nasopharyngeal Cancer Industry to 2028 - North America is the Fastest Growing Region - ResearchAndMarkets.com

Retrieved on: 
Friday, January 6, 2023

The symptoms of nasopharyngeal cancer include a lump in the neck, hearing loss, stuffiness, numbness, frequent headaches, fatigue, blurred, weight loss etc.

Key Points: 
  • The symptoms of nasopharyngeal cancer include a lump in the neck, hearing loss, stuffiness, numbness, frequent headaches, fatigue, blurred, weight loss etc.
  • According to the American Institute for Cancer Research estimates, Nasopharyngeal cancer is the 23rd most common cancer worldwide, and it is the 18th most commonly occurring cancer in men and the 22nd most commonly occurring cancer in women.
  • Thus, the high prevalence rate of nasopharyngeal cancer will increase the demands for effective drugs and therapies that will further lead to market growth.
  • The global nasopharyngeal cancer market is segmented based on cancer type, diagnosis method, and therapy.

Genius Group Announced the Initial Results of Its Shares Market Activity Investigation

Retrieved on: 
Wednesday, January 4, 2023

Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading entrepreneur edtech and education group, announces today that the Initial results of the investigation made by Christian Levine Law Group and Warshaw Burstein, LLP, indicates that certain individuals and/or companies appear to have sold (but not delivered) a significant amount of the stock of the company, which is illegal and appears to be part of a market manipulation scheme seeking to artificially depress the price of the securities of the company.

Key Points: 
  • Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading entrepreneur edtech and education group, announces today that the Initial results of the investigation made by Christian Levine Law Group and Warshaw Burstein, LLP, indicates that certain individuals and/or companies appear to have sold (but not delivered) a significant amount of the stock of the company, which is illegal and appears to be part of a market manipulation scheme seeking to artificially depress the price of the securities of the company.
  • The company will continue to investigate who is responsible for manipulating its share price and will aggressively pursue all remedies against any and all parties responsible for damaging the company.

EzFill Adds Ten Fleet Accounts in November

Retrieved on: 
Tuesday, December 6, 2022

MIAMI, FL, Dec. 06, 2022 (GLOBE NEWSWIRE) -- EzFill Holdings, Inc. (“EzFill” or the “Company”) (NASDAQ: EZFL), a pioneer and emerging leader in the mobile fuel industry, announced it added over 10 new fleet accounts during the month of November, bringing to over 85 the number of fleet accounts added in 2022.

Key Points: 
  • MIAMI, FL, Dec. 06, 2022 (GLOBE NEWSWIRE) -- EzFill Holdings, Inc. (“EzFill” or the “Company”) (NASDAQ: EZFL), a pioneer and emerging leader in the mobile fuel industry, announced it added over 10 new fleet accounts during the month of November, bringing to over 85 the number of fleet accounts added in 2022.
  • Mike McConnell, EzFill Chief Executive Officer, commented, “We’re very pleased with our continued progress.
  • The new fleet account additions are a testament to the growing recognition of EzFill as a value-added service among Florida businesses.
  • EzFill is a leader in the fast-growing mobile fuel industry, with the largest market share in its home state of Florida.

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting

Retrieved on: 
Monday, December 5, 2022

clonoSEQ testing for diffuse large B-cell lymphoma (DLBCL) patients is currently available for clinical use as a laboratory-developed test (LDT) performed at Adaptive's CLIA-certified lab in Seattle, WA.

Key Points: 
  • clonoSEQ testing for diffuse large B-cell lymphoma (DLBCL) patients is currently available for clinical use as a laboratory-developed test (LDT) performed at Adaptive's CLIA-certified lab in Seattle, WA.
  • clonoSEQ ctDNA-based MRD testing in DLBCL has also been approved by New York State's Clinical Laboratory Evaluation Program (CLEP).
  • The clonoSEQ Assay leverages Adaptive Biotechnologies’ proprietary immune medicine platform to identify and quantify specific DNA sequences found in malignant cells, allowing clinicians to assess and monitor MRD during and after treatment.
  • Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases.

TraceyBryantStuckey.com Congratulates all of the National Board Certified Teachers on Score Release Day

Retrieved on: 
Saturday, December 10, 2022

TraceyBryantStuckey.com would like to say "Congratulations on this significant accomplishment that makes you shine as one of the best teachers in our nation!"

Key Points: 
  • TraceyBryantStuckey.com would like to say "Congratulations on this significant accomplishment that makes you shine as one of the best teachers in our nation!"
  • Candidates complete a series of rigorous components that culminate in a portfolio scored at the national level ensuring the highest level of authenticity.
  • This can be a day of celebration for those achieving or maintaining certification, however this day is also somber for those who do not achieve.
  • For the most current and up to date offerings, be sure to visit current offerings for teachers at www.traceybryantstuckey.com .